EP
MRTX

Elkfork Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Elkfork Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$19K Hold
242
– – ﹤0.01% 1035
2019
Q2 		$25K Hold
242
– – ﹤0.01% 1024
2019
Q1 		$18K Buy
+242
New +$16.5K ﹤0.01% 1020

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Elkfork Partners's MRTX Position: Q3 2019 in Review

Elkfork Partners held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q3 2019 at 242 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Elkfork Partners first reported a position in MRTX in Q1 2019 and has held it in 3 quarters since. The position peaked at $25K in Q2 2019. 177 funds tracked by Wall St. Rank hold MRTX as of Q3 2019.

  • Elkfork Partners held 242 shares of Mirati Therapeutics, Inc. Common Stock worth $19K as of Q3 2019.
  • Elkfork Partners left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q3 2019.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1035 holding.
  • Elkfork Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and has held it in 3 quarters since.
  • Elkfork Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $25K in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.